The first approved therapy for HER2+ BC was adjuvant chemotherapy called trastuzumab, which consists of a humanized monoclonal Ab that specifically recognizes HER2, inhibiting HER2 dimerization [87]. Here, ERBB2 is linked to breast cancer.